Cibc World Market Inc. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 26.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 700,174 shares of the company’s stock after acquiring an additional 145,527 shares during the quarter. Cibc World Market Inc.’s holdings in Novo Nordisk A/S were worth $35,625,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in NVO. Quotient Wealth Partners LLC lifted its position in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock worth $463,000 after purchasing an additional 177 shares in the last quarter. Certuity LLC grew its position in Novo Nordisk A/S by 3.6% during the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after purchasing an additional 177 shares in the last quarter. Oakworth Capital Inc. grew its position in Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares in the last quarter. True North Advisors LLC increased its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after buying an additional 199 shares during the period. Finally, Asio Capital LLC increased its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock valued at $274,000 after buying an additional 200 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.
Novo Nordisk A/S Stock Performance
Shares of NVO opened at $43.74 on Friday. The firm has a market cap of $195.29 billion, a price-to-earnings ratio of 10.27, a price-to-earnings-growth ratio of 3.75 and a beta of 0.78. The company’s fifty day moving average is $41.49 and its 200-day moving average is $46.20. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Citigroup reiterated a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, May 12th. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Finally, Wolfe Research assumed coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $65.56.
Get Our Latest Stock Analysis on NVO
Key Stories Impacting Novo Nordisk A/S
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Novo Nordisk is getting a lift from investor anticipation ahead of the American Diabetes Association 2026 Scientific Sessions and its June 7 R&D investor event, where the company is expected to highlight new cardiometabolic pipeline and portfolio data. Novo Nordisk gains as investors position for ADA data and June 7 R&D event
- Positive Sentiment: The company also launched Wegovy in the United Arab Emirates, its first market outside the U.S. for the oral weight-loss pill, signaling continued international expansion for its obesity franchise. Novo Nordisk launches Wegovy in UAE
- Positive Sentiment: Veru’s announcement that it will study enobosarm alongside Novo Nordisk’s Wegovy in a Phase 2b obesity trial adds another external validation point for Wegovy’s role in combination therapy research. Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial
- Neutral Sentiment: Macro headlines also noted that Novo Nordisk products are supporting Danish export growth, but this is more of a broader economic backdrop than a direct stock-specific driver. Novo Exports Help Danish Economy Outpace Europe, Danske Says
- Negative Sentiment: Competition remains a concern, as Eli Lilly continues to be viewed as an aggressive rival in GLP-1/obesity drugs, which can cap enthusiasm for Novo Nordisk’s long-term market share. Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
Featured Articles
- Five stocks we like better than Novo Nordisk A/S
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
